Live Breaking News & Updates on அசை அழுத்தம் சிகிச்சை
Stay updated with breaking news from அசை அழுத்தம் சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
E-Mail The Mark Foundation for Cancer Research announces a $1 million grant to The Jackson Laboratory (JAX) to study the harmful side effects that sometimes occur in cancer patients treated with immunotherapy. The research will involve mice engineered with humanized immune systems to find specific gene variants that could explain why so many patients - as many as 10 percent - develop Type 1 diabetes while undergoing immunotherapy to treat cancer. The grant will also study and determine how to predict which patients may experience myocarditis, a rare but potentially deadly inflammation of the heart that immunotherapy can also trigger. This new grant project, Identifying Genes Uniquely Contributing to ICI-induced Immune Related Adverse Events, led by Professor Dave Serreze, Ph.D., and Scientific Director and Professor Nadia Rosenthal, Ph.D., F.Med.Sci., builds upon a $2.5 million grant the Mark Foundation awarded to JAX in 2019 aimed at determining how genetics influence i ....
Dive Brief: Roche will work with Ribometrix to develop chemical-based drugs aimed at targets on RNA molecules, the small Durham, North Carolina biotech announced Wednesday. The Swiss pharma will pay Ribometrix $25 million to kick off the deal, which is heavily backloaded with conditional payments that could exceed $1 billion if certain milestones are hit. The two will collaborate on preclinical development, after which Roche s Genentech division will be responsible for clinical testing and commercialization. The agreement is the second collaboration of its kind Roche has struck since April, when the company partnered with another privately held biotech, Arrakis Therapeutics. Large drugmakers are pushing into the emerging field of research, which offers a way to reach drug targets inside cells that are difficult to get at through other methods. ....
Dive Brief: Vertex will pay privately held biotech Skyhawk Therapeutics $40 million up front in a deal to develop small molecule drugs that can modify RNA and treat unspecified serious diseases. The agreement gives Vertex options to license rights to programs that come from the work, after which the big biotech would take the lead on development and commercialization. The deal is heavily backloaded, including up to $2.2 billion in downstream payments as well as royalties that would only materialize if all goes well. The alliance continues a string of deals for Vertex in untraditional fields of scientific research such as targeted protein degradation, messenger RNA therapeutics and gene editing, part of a plan to lessen its reliance on its core cystic fibrosis franchise. It also marks the latest indication of biopharma interest in chemical-based drugs that target RNA. ....